The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease
Open accessAbstract
BACKGROUND: Previous trials have shown that the use of statins to lower cholesterol reduces the risk of cardiovascular events among persons without cardiovascular disease. Those trials have involved persons with elevated lipid levels or inflammatory markers and involved mainly white persons. It is unclear whether the benefits of statins can be extended to an intermediate-risk, ethnically diverse population without cardiovascular disease. METHODS: In one comparison from a 2-by-2 factorial trial, we randomly assigned 12,705 participants in 21 countries who did not have cardiovascular disease and were at intermediate risk to receive rosuvastatin at a dose of 10 mg per day or placebo. The first coprimary outcome was the composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, and the second coprimary outcome additionally included revascularization, heart failure, and resuscitated cardiac arrest. The median follow-up was 5.6 years. RESULTS: The overall mean low-density lipoprotein cholesterol level was 26.5% lower in the rosuvastatin group than in the placebo group. The first coprimary outcome occurred in 235 participants (3.7%) in the rosuvastatin group and in 304 participants (4.8%) in the placebo group (hazard ratio, 0.76; 95% confidence interval [CI], 0.64 to 0.91; P=0.002). The results for the second coprimary outcome were consistent with the results for the first (occurring in 277 participants [4.4%] in the rosuvastatin group and in 363 participants [5.7%] in the placebo group; hazard ratio, 0.75; 95% CI, 0.64 to 0.88; P<0.001). The results were also consistent in subgroups defined according to cardiovascular risk at baseline, lipid level, C-reactive protein level, blood pressure, and race or ethnic group. In the rosuvastatin group, there was no excess of diabetes or cancers, but there was an excess of cataract surgery (in 3.8% of the participants, vs. 3.1% in the placebo group; P=0.02) and muscle symptoms (in 5.8% of the participants, vs. 4.7% in the placebo group; P=0.005). CONCLUSIONS: Treatment with rosuvastatin at a dose of 10 mg per day resulted in a significantly lower risk of cardiovascular events than placebo in an intermediate-risk, ethnically diverse population without cardiovascular disease. (Funded by the Canadian Institutes of Health Research and AstraZeneca; HOPE-3 ClinicalTrials.gov number, NCT00468923.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“First, there are three large, randomized trials of statin versus placebo where specific cognitive tests were performed, and no differences were seen between statin and placebo (166-169).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [169]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“First, there are three large, randomized trials of statin versus placebo where specific cognitive tests were performed, and no differences were seen between statin and placebo (160–163).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [163]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The Heart Outcomes Prevention Evaluation 3 (HOPE-3), published in 2016, showed that low-dose statin therapy reduced the composite cardiovascular outcome by 24% but had no significant effect on mortality.19”
From Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients (2023) · cites this paper as [19]
Experimental — accuracy not yet measuredIn the citing paper
“The effectiveness of statins for preventing the first occurrence and recurrence of stroke in Japanese populations was confirmed in a sub-analysis of the MEGA study620, 621) and in the JELIS study622).”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [621]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yusuf, S., Hawken, S., Ôunpuu, S., Dans, T., Avezum, A., Lanas, F., McQueen, M., Budaj, A., Pais, P., Varigos, J., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17018-9 · Cited by 12,026
Self-citationForouzanfar, M. H., Afshin, A., Alexander, L. T., Anderson, H. R., Bhutta, Z. A., Biryukov, S., Brauer, M., Burnett, R., Cercy, K., Charlson, F. J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31679-8 · Cited by 7,698
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Proportional hazards tests and diagnostics based on weighted residuals
GRAMBSCH, P. M., & THERNEAU, T. M. (1994) · Biometrika · doi:10.1093/biomet/81.3.515 · Cited by 5,885
Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J. J., Gotto, A. M., Kastelein, J. J. P., Köenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000344393.60303.0a · Cited by 3,641
O'Donnell, M. J., Xavier, D., Liu, L., Zhang, H., Chin, S. L., Rao-Melacini, P., Rangarajan, S., Islam, S., Pais, P., McQueen, M. J., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60834-3 · Cited by 3,448
Self-citationCollaborators, C. T. T. (. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60367-5 · Cited by 2,833
Forouzanfar, M. H., Alexander, L., Anderson, H. R., Bachman, V. F., Biryukov, S., Brauer, M., Burnett, R., Casey, D., Coates, M. M., Cohen, A., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00128-2 · Cited by 2,701
Semiparametric regression for the mean and rate functions of recurrent events
Lin, D. Y., Wei, L. J., Yang, I., & Ying, Z. (2000) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/1467-9868.00259 · Cited by 969
Flagged first, then by citations
Research works printed but not linked: 1
- Sackett DL, 2000, CMAJ, 162, 1311
Cited by
Sorted by citations
Items 301–400 of 847
Gupta, A., Thompson, D., Whitehouse, A., Collier, T. J., Dahlöf, B., Poulter, N. R., Collins, R., Sever, P., & A RUGBE Investigators (2018) · Yearbook of pediatric endocrinology · doi:10.1530/ey.15.14.12 · Cited by 18
Li, F.-H., Huang, X., Wang, H., Guo, S., & Li, P. (2020) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(20)60018-8 · Cited by 18
Premature Death in Kidney Transplant Recipients: The Time for Trials is Now
Vinson, A. J., Singh, S., Chadban, S., Cherney, D., Gaber, A. O., Gill, J. S., Helgeson, E., Herzog, C. A., Jardine, M., Jha, V., et al. (2022) · Journal of the American Society of Nephrology · doi:10.1681/asn.2021111517 · Cited by 18
Epicardial Fat in Heart Failure with Preserved Ejection Fraction: Bad Actor or Just Lying Around?
Oduah, M.-T. A., Sundaram, V., & Reddy, Y. N. V. (2023) · Cardiac failure review · doi:10.15420/cfr.2022.25 · Cited by 18
Bittner, V., Linnebur, S. A., Dixon, D. L., Forman, D. E., Green, A. R., Jacobson, T. A., Orkaby, A. R., Saseen, J. J., & Virani, S. S. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.09.005 · Cited by 20
Pletcher, M. J., Pignone, M. P., Jarmul, J. A., Moran, A. E., Vittinghoff, E., & Newman, T. B. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.004316 · Cited by 18
López-Jaramillo, P. A., González‐Gómez, S., Zarate-Bernal, D., Serrano, A., Atuesta, L., Clausen, C., Castro-Valencia, C., Camacho, P. A., & Otero, J. A. (2018) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944718764588 · Cited by 18
Self-citationClinician's Guide to the Updated ABCs of Cardiovascular Disease Prevention: A Review Part 1
Arps, K. E., Pallazola, V. A., Cardoso, R. N., Meyer, J., Jones, R., Latina, J. M., Gluckman, T. J., Stone, N. J., Blumenthal, R. S., & McEvoy, J. W. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2019.01.016 · Cited by 18
Heseltine, T., Murray, S. W., Ruzsics, B., & Fisher, M. (2020) · European Cardiology Review · doi:10.15420/ecr.2019.14.2 · Cited by 19
Schweitzer, A. M., Gingrich, M. A., Hawke, T. J., & Rebalka, I. A. (2020) · European Journal of Applied Physiology · doi:10.1007/s00421-020-04360-2 · Cited by 22
Bragança, B., & Correia‐de‐Sá, P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21145005 · Cited by 18
García-Gil, M., Comas‐Cufí, M., Blanch, J., Martí‐Lluch, R., Ponjoan, A., Alves‐Cabratosa, L., Petersen, I., Marrugat, J., Elosúa, R., Grau, M., et al. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.954 · Cited by 19
Kalra, D. K., Ray, K. K., Bajaj, A., Kushner, P. R., Wilcox, M. L., Dicklin, M. R., Kirkpatrick, C. F., & Maki, K. C. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.02.006 · Cited by 18
Residual inflammatory risk after contemporary lipid lowering therapy
Riaz, H., Khan, S. U., Lateef, N., Talluri, S., Khan, M. S., & Desai, M. Y. (2019) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcz055 · Cited by 18
Medications for Lipid Control: Statins vs Newer Drugs
McPherson, R., Adreak, N., & Sharma, A. (2024) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2024.05.004 · Cited by 17
Zoungas, S., Moran, C., Curtis, A. J., Spark, S., Flanagan, Z., Beilin, L. J., Chong, T. T. ‐., CLOUD, G. C., Hopper, I., Kost, A., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.124.036357 · Cited by 18
Self-citationLi, H., Hu, Y. J., Lin, H., Xia, H., Guo, Y., & Wu, F. (2020) · American Journal of Hypertension · doi:10.1093/ajh/hpaa146 · Cited by 17
Saeed, A., Virani, S. S., Mulukutla, S. R., & Chow, C. K. (2021) · Current Diabetes Reviews · doi:10.2174/1573399817999210112192419 · Cited by 18
Novel Mouse Model of Coronary Atherosclerosis With Myocardial Infarction: Insights Into Human CAD
Chen, H., Wan, Q., Yang, J., Rao, H., Xu, C., Xu, P., Yang, X., Wang, H. Y.-C., Feng, W., Wang, L., et al. (2025) · Circulation Research · doi:10.1161/circresaha.125.326409 · Cited by 15
Effect of statin on life prognosis in Japanese patients undergoing hemodialysis
Ota, Y., Kitamura, M., Muta, K., Yamashita, H., Uramatsu, T., Obata, Y., Harada, T., Funakoshi, S., Mukae, H., & Nishino, T. (2019) · PLoS ONE · doi:10.1371/journal.pone.0224111 · Cited by 16
Mannucci, E., & Silverii, G. A. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15226 · Cited by 16
Kumar, A., Shariff, M., & Doshi, R. P. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319868035 · Cited by 16
Gnanenthiran, S. R., Ng, A. C. C., Cumming, R. G., Brieger, D. B., Couteur, D. G. L., Waite, L. M., Handelsman, D. J., Naganathan, V., Kritharides, L., & Blyth, F. (2019) · Heart · doi:10.1136/heartjnl-2019-315449 · Cited by 16
Azadnajafabad, S., Karimian, M. S., Roshani, S., Rezaei, N., Mohammadi, E., Moghaddam, S. S., Ghasemi, E., Morasa, F. S., Rezaei, N., Aminorroaya, A., et al. (2020) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-020-00673-3 · Cited by 16
Favourable impact of statin use on diastolic blood pressure levels
Tocci, G., Presta, V., Citoni, B., Figliuzzi, I., Coluccia, R., Battistoni, A., Musumeci, B., Biase, L. D., Ferrucci, A., & Volpe, M. (2017) · Journal of Hypertension · doi:10.1097/hjh.0000000000001419 · Cited by 16
de Paula, T. P., Santos, P. C., Arifa, R. D. D. N., Vieira, A. T., Baltazar, L. D. M., Ávila, T. V., Fagundes, C. T., Garcia, Z. M., Lima, R. L., Teixeira, M. M., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00764-17 · Cited by 17
Zhang, X., Lan, R., Zhang, X., Xu, W., Wang, L., Kang, L., & Xu, B. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.012428 · Cited by 15
Hypertension mediated kidney and cardiovascular damage and risk stratification: Redefining concepts
Márquez, D. F., Rodríguez‐Sánchez, E., Segura, J., Ruilope, L. M., & Ruiz‐Hurtado, G. (2022) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2021.10.008 · Cited by 18
Pandey, K. R., & Meltzer, D. O. (2016) · PLoS ONE · doi:10.1371/journal.pone.0155293 · Cited by 15
Targeting LDL Cholesterol: Beyond Absolute Goals Toward Personalized Risk
Leibowitz, M., Cohen-Stavi, C. J., Basu, S., & Balicer, R. D. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0858-6 · Cited by 15
Changing concepts in hypertension management
Gudsoorkar, P. S., & Tobe, S. W. (2017) · Journal of Human Hypertension · doi:10.1038/jhh.2017.57 · Cited by 15
Campbell, D. J., Coller, J. M., Gong, F. F., McGrady, M., Prior, D., Boffa, U., Shiel, L. M., Liew, D., Wolfe, R. S., Owen, A. J., et al. (2017) · Internal Medicine Journal · doi:10.1111/imj.13678 · Cited by 15
Self-citationHit or miss: the new cholesterol targets
DuBroff, R. J., Malhotra, A., & de Lorgeril, M. (2020) · BMJ Evidence-Based Medicine · doi:10.1136/bmjebm-2020-111413 · Cited by 17
Angelis, D. D., Squeo, G., Pasqualone, A., & Summo, C. (2021) · Journal of Food Science and Technology · doi:10.1007/s13197-021-05288-x · Cited by 15
Maggioni, A. P., Calabria, S., Rossi, E., & Martini, N. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.02.108 · Cited by 15
Statins: Rationale, Mode of Action, and Side Effects
Sultan, S., D'Souza, A., Zabetakis, I., Lordan, R., Τσούπρας, Α., Kavanagh, E. P., & Hynes, N. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813792-5.00006-9 · Cited by 18
Bempedoic Acid: A New Drug for an Old Problem
Nguyen, D., Du, N., Sulaica, E. M., & Wanat, M. A. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028020941083 · Cited by 15
Intensive Blood Pressure Control in Older Patients With Hypertension
Song, Q., Peng, X., Bai, J., Yang, R., Ling, Q., Chen, S., Ji, Y., Dong, X., Wang, X., Wu, S., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.06.045 · Cited by 15
Bosmans, L. A., Shami, A., Atzler, D., Weber, C., Gonçalves, I., & Lutgens, E. (2021) · Vascular Pharmacology · doi:10.1016/j.vph.2021.106884 · Cited by 14
The Era of Polypills in the Management of Cardiovascular Diseases: Are We There Yet?
Khan, A. A., Siddiqui, S. A., Yasmin, F., Abidi, S. M., Tariq, R., Ahmed, H., Murtaza, N., Jawed, F., Lashkerwala, S. S., Moin, A., et al. (2022) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2022.101233 · Cited by 14
Shah, N. P., Page, C. B., Green, C. L., Gao, M., Cavalier, J. S., McGarrah, R. W., DeWald, T. A., Sangvai, D. G., Patel, M. R., & Pagidipati, N. J. (2022) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2022.10.033 · Cited by 14
Incidence of Statin-Associated Adverse Events in Kidney Transplant Recipients
Bae, S., Ahn, J. B., Joseph, C., Whisler, R., Schnitzler, M. A., Lentine, K. L., KADOSH, B. S., Segev, D. L., & McAdams‐DeMarco, M. (2023) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000000000124 · Cited by 13
Polypill in cardiovascular disease prevention: recent advances
Coca, A., Castellano, J. M., Camafort, M., & Fuster, V. (2023) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.16460 · Cited by 15
The Effect of Statins on Ocular Disorders: A Systematic Review of Randomized Controlled Trials
Lymperopoulou, C., Kandarakis, S., Tzanaki, I., Mylona, I., Xanthos, T. T., & Agouridis, A. P. (2023) · Pharmaceuticals · doi:10.3390/ph16050711 · Cited by 14
Weir, M. R. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15764 · Cited by 16
Management of Elderly Patients with Chronic Kidney Disease
Park, Y., & Hwang, W. M. (2024) · Yonsei Medical Journal · doi:10.3349/ymj.2024.0178 · Cited by 16
Bittner, V., Linnebur, S. A., Dixon, D. L., Forman, D. E., Green, A. R., Jacobson, T. A., Orkaby, A. R., Saseen, J. J., & Virani, S. S. (2025) · Journal of the American Geriatrics Society · doi:10.1111/jgs.19398 · Cited by 15
Huang, B., Peng, Y., Huang, F., Xia, T., Gui, Y.-Y., Liao, Y., Pu, X., Chen, S.-J., Yang, Y., & Chen, M. (2017) · Internal and Emergency Medicine · doi:10.1007/s11739-017-1694-9 · Cited by 14
Pavlović, J., Greenland, P., Deckers, J. W., Kavousi, M., Albert Hofman, D., Ikram, M. A., Franco, O. H., & Leening, M. J. G. (2017) · European Journal of Preventive Cardiology · doi:10.1177/2047487317743352 · Cited by 14
Berkley, A., & Ferro, A. (2020) · JRSM Cardiovascular Disease · doi:10.1177/2048004020929235 · Cited by 14
Orringer, C. E., & Maki, K. C. (2020) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2020.01.016 · Cited by 14
Hoang, T., & Kim, J. (2020) · Nutrients · doi:10.3390/nu12082218 · Cited by 15
Silverwatch, J., Marti, K. E., Phan, M. T., Amin, H., Roman, Y. M., Pasupuleti, V., Banach, M., Barboza, J. J., & Hernández, A. V. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10040782 · Cited by 14
Semen parameters are unaffected by statin use in men evaluated for infertility
Keihani, S., Martin, C., Craig, J. R., Zhang, C., Presson, A. P., Myers, J. B., Aston, K. I., Emery, B. R., Carrell, D. T., & Hotaling, J. M. (2018) · Andrologia · doi:10.1111/and.12995 · Cited by 14
Statin therapy for young adults: A long-term investment worth considering
Miedema, M. D., Nauffal, V. D., Singh, A., & Blankstein, R. (2019) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2019.02.004 · Cited by 14
No Such Thing as Ideal Blood Pressure
Fuster, V. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.05.005 · Cited by 14
Cardiovascular Risk Assessment and Lipid-Lowering Therapy Recommendations in Primary Prevention
Komnianou, A., Kyriakoulis, K. G., Menti, A., Dimakakos, E. P., Stergiou, G. S., & Κόλλιας, Α. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14072220 · Cited by 15
Drug Discovery for Coronary Artery Disease
Wan, Q., Qian, S., Yonghu, H., Zhang, Y., Peng, Z., Li, Q., Shu, B., Zhu, L., & Wang, M. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-2517-9_8 · Cited by 13
Jung, H. N., Kim, M., Kim, H. S., Lee, W. J., Min, S. H., Kim, Y., & Jung, C. H. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.024637 · Cited by 13
Self-citationBabadagli, H. E., Barry, A. R., Thanassoulis, G., & Pearson, G. J. (2023) · Canadian Pharmacists Journal / Revue des Pharmaciens du Canada · doi:10.1177/17151635231164989 · Cited by 12
Karavasili, C., Babaee, S., Kutty, S., Chu, J. N., Min, S., Fitzgerald, N. J., Morimoto, J., Inverardi, N., & Traverso, G. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202301101 · Cited by 12
Degree of Risk Factor Control and Incident Cardiovascular Diseases in Patients With Hypertension
Kou, M., Wang, X., Ma, H., Li, X., Heianza, Y., & Qi, L. (2024) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2023.05.008 · Cited by 12
Cholesterol Lowering in Older Adults: Should We Wait for Further Evidence?
Jamil, Y., Cohen, R., Alameddine, D., Deo, S. V., Kumar, M., & Orkaby, A. R. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01224-4 · Cited by 13
Associations between Statin Use and Glaucoma in the All of Us Research Program
Lee, S. Y., Paul, M., Coleman, A. L., Kitayama, K., Yu, F., Pan, D., & Tseng, V. L. (2024) · Ophthalmology Glaucoma · doi:10.1016/j.ogla.2024.07.008 · Cited by 13
Recent Pathophysiological Insights Are Advancing the Treatment of Venous Thromboembolism
Singh, S., Kumar, P., Yadav, S. K., Jaffer, F. A., & Reed, G. L. (2025) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2024.12.004 · Cited by 13
Statin Therapy as Primary Prevention in Exercising Adults: Best Evidence for Avoiding Myalgia
Bosomworth, N. J. (2016) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2016.06.160085 · Cited by 14
Filho, M. M. P., Brant, L. C. C., dos Reis, R. C. P., Giatti, L., Duncan, B. B., Lotufo, P. A., da Fonseca, M. D. J. M., Mill, J. G., de Almeida, M. D. C. C., Macfarlane, P. W., et al. (2020) · Heart · doi:10.1136/heartjnl-2020-318097 · Cited by 13
Prevention of Coronary Heart Disease: A Translational Clinical Challenge
Giannini, J., Padilla, J., Eaton, R. P., Gonzales, K. M., & Schade, D. S. (2022) · World Journal of Cardiovascular Diseases · doi:10.4236/wjcd.2022.121002 · Cited by 13
Role of HDL-Associated Proteins and Lipids in the Regulation of Inflammation
White, R., Giordano, S. S., & Datta, G. (2017) · InTech eBooks · doi:10.5772/67141 · Cited by 15
Mazza, A., Schiavon, L., Rigatelli, G., Torin, G., & Lenti, S. (2019) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-019-00332-6 · Cited by 13
Panozzo, C. A., Curtis, L. H., Marshall, J. H., Fine, L. J., Wells, B. L., Brown, J. S., Haynes, K., Pawloski, P. A., Hernandez, A. F., Malek, S., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0223515 · Cited by 13
Analysis of Intrinsic and Extrinsic Coagulation Pathway Factors in OCP Treated PCOS Women
Manzoor, S., Ganie, M. A., Majid, S., Shabir, I., Kawa, I. A., Fatima, Q., Jeelani, H., Yousuf, S. D., & Rashid, F. (2020) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-020-00901-w · Cited by 13
Ennezat, P., Cosgrove, S., Bouvaist, H., Maréchaux, S., Guerbaaï, R.-A., Jemtel, T. H. L., Andréjak, M., & Vital-Durand, D. (2017) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2017.01.011 · Cited by 13
Statin Therapy for Primary and Secondary Prevention in Older Adults
Bao, A., & Karalis, D. G. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01257-9 · Cited by 12
Mancini, G. B. J., Ryomoto, A., Yeoh, E., Iatan, I., Brunham, L. R., & Hegele, R. A. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf048 · Cited by 12
Jackson, R., Kerr, A., & Wells, S. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw322 · Cited by 12
Turgeon, R. D., Anderson, T. J., Grégoire, J., & Pearson, G. J. (2017) · Canadian Pharmacists Journal / Revue des Pharmaciens du Canada · doi:10.1177/1715163517713031 · Cited by 3
Liu, Z., Gong, S., Wang, Y., Chen, T., Niu, Y., & Xu, Y. (2020) · ACS Applied Bio Materials · doi:10.1021/acsabm.9b01089 · Cited by 12
Batty, G. D., & Mika Kivimaki, B. (2021) · Journal of Epidemiology & Community Health · doi:10.1136/jech-2020-215870 · Cited by 12
Redefining the polypill: pros and cons in cardiovascular precision medicine
Birla, S., Angural, A., Madathumchalil, A., Shende, R. V., Shastry, S. V., Mahadevappa, M., Shambhu, S. K., Vishwanath, P., & Prashant, A. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1268119 · Cited by 12
Malekzadeh, F., Gandomkar, A., Poustchi, H., Etemadi, A., Roshandel, G., Attar, A., Abtahi, F., Boogar, S. S., Mohammadkarimi, V., Fattahi, M. R., et al. (2024) · Heart · doi:10.1136/heartjnl-2023-323614 · Cited by 13
Nedogoda, S. V., Chumachek, E. V., Ledyaeva, A. A., Цома, В. В., Salasyuk, A. S., Смирнова, В. О., Hripaeva, V. Y., Витальевич, П. Р., & Popova, E. A. (2018) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2018-4-49-55 · Cited by 12
Current European guidelines on arterial hypertension: new positions and unsolved issues
Кобалава, Ж. Д., Kolesnik, E. L., & Троицкая, Е. А. (2019) · Clinical pharmacology and therapy · doi:10.32756/0869-5490-2019-2-7-18 · Cited by 11
Advancing antihypertensive drug development
Pu, F., Liu, Y., Ahmed, F. Z., Wang, X., Green, D., & Zhang, H. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70063 · Cited by 15
Rifai, M. A., Blumenthal, R. S., Stone, N. J., Schofield, R. S., Orringer, C. E., Michos, E. D., Heidenreich, P. A., Braun, L. T., Birtcher, K. K., Smith, S. C., et al. (2021) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2021.08.001 · Cited by 11
Nguyen, B., Crijns, H. J. G. M., Tijssen, J. G. P., Geelhoed, B., Hobbelt, A. H., Hemels, M. E. W., Mol, W. J. M., Weijs, B., Alings, M., Smit, M. D., et al. (2021) · EP Europace · doi:10.1093/europace/euab270 · Cited by 13
Hypertension mediated kidney and cardiovascular damage and risk stratification: Redefining concepts
Márquez, D. F., Rodríguez‐Sánchez, E., Segura, J., Ruilope, L. M., & Ruiz‐Hurtado, G. (2021) · Nefrología · doi:10.1016/j.nefro.2021.10.003 · Cited by 13
Statins and risk of venous thromboembolic diseases: A two-sample mendelian randomization study
Ma, X.-S., Sun, J., Geng, R., Zhao, Y., Xu, W.-Z., Liu, Y., Jiang, Y., & Li, Y. (2023) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2023.02.023 · Cited by 11
Reflections on Neuroprotection Research and the Path Toward Clinical Success
Lapchak, P. A., & Boitano, P. D. (2017) · Springer series in translational stroke research · doi:10.1007/978-3-319-45345-3_1 · Cited by 11
Investigating potential mediator between statin and coronary artery calcification
Lee, D., Joo, H. J., Jung, H.-W., & Lim, D. (2018) · PLoS ONE · doi:10.1371/journal.pone.0203702 · Cited by 11
Self-citationThe cost implication of primary prevention in the HOPE 3 trial
Lamy, A. L., Lonn, E., Tong, W., Swaminathan, B., Jung, H., Gafni, A., Bosch, J., & Yusuf, S. (2019) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcz001 · Cited by 11
Self-citationTime‐Dependent Cardiovascular Treatment Benefit Model for Lipid‐Lowering Therapies
Khan, I., Peterson, E. D., Cannon, C. P., Sedita, L. E., Edelberg, J. M., & Ray, K. K. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.016506 · Cited by 10
The Unchartered Frontier: Preventive Cardiology Between the Ages of 15 and 35 Years
Gooding, H. C., & Johnson, H. M. (2016) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-016-0509-2 · Cited by 11
Masson, W. M., Lobo, M., Siniawski, D. A., Molinero, G., Huerin, M. S., & Nogueira, J. P. (2019) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-019-00330-8 · Cited by 10
Blood-Pressure and Cholesterol Lowering in the HOPE-3 Trial
Lonn, E. M., Jung, H., & Yusuf, S. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1608916 · Cited by 11
Self-citationAtorvastatin, Cardiovascular Events, and Disability-free Survival in Older Adults
Zoungas, S., Wolfe, R. S., Moran, C., Nicholls, S. J., CLOUD, G. C., Reid, C. M., Τonkin, A. M., Beilin, L., Wierzbicki, A. S., Chong, T. T.-J., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2607314 · Cited by 13
Self-citationLegacy in Cardiovascular Risk Factors Control: From Theory to Future Therapeutic Strategies?
Pothen, L., & Balligand, J. (2021) · Antioxidants · doi:10.3390/antiox10111849 · Cited by 11
Wu, W., Chen, Y., Wu, K., Zheng, H., Chen, G., Wang, X., Huang, Z., Cai, Z., Cai, Z., Chen, Z., et al. (2023) · Clinical and Experimental Hypertension · doi:10.1080/10641963.2023.2264540 · Cited by 10
Lamy, A. L., Tong, W., Joseph, P. G., Gao, P., Huffman, M. D., Roshandel, G., Malekzadeh, R., López-Jaramillo, P. A., Pais, P. S., Xavier, D., et al. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102651 · Cited by 10
Self-citationLolekha, P., Khovidhunkit, W., Deerochanawong, C., Thongtang, N., Boonyasirinant, T., Rattarasarn, C., Chutinet, A., Ophascharoensuk, V., Somlaw, N., Sitthisook, S., et al. (2024) · Asian Biomedicine · doi:10.2478/abm-2024-0033 · Cited by 13
Metadata
- Authors
- Yusuf, S., Bosch, J., Dagenais, G., Zhu, J., Xavier, D., Liu, L., Pais, P., López-Jaramillo, P., Leiter, L. A., Dans, A., Avezum, A., Piegas, L. S., Parkhomenko, A., Keltai, K., Keltai, M., Sliwa, K., Peters, R. J. G., Held, C., Chazova, I., Yusoff, K., Lewis, B. S., Jansky, P., Khunti, K., Toff, W. D., Reid, C. M., Varigos, J., Sanchez-Vallejo, G., McKelvie, R., Pogue, J., Jung, H., Gao, P., Diaz, R., & Lonn, E.
- Affiliations
- St. Michael's Hospital (CA)
- Semmelweis University (HU)
- Uppsala University (SE)
- ORCID
- Yusuf, Salim
- Bosch, Jackie
- Dagenais, Gilles
- Zhu, Jun
- Xavier, Denis
- Liu, Lisheng
- Pais, Prem
- López-Jaramillo, Patricio
- Leiter, Lawrence A.
- Piegas, Leopoldo S.
- Parkhomenko, Alexander
- Keltai, Katalin
- Sliwa, Karen
- Peters, Ron J.G.
- Held, Claes
- Chazova, Irina
- Yusoff, Khalid
- Lewis, Basil S.
- Khunti, Kamlesh
- Toff, William D.
- Reid, Christopher M.
- McKelvie, Robert
- Jung, Hyejung
- Lonn, Eva
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-05-26
- Volume
- 374
- Issue
- 21
- Pages
- 2021-2031
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2313998826
- Cited by
- 848
- References
- 23
- Citations by year
- 2026: 32 · 2025: 52 · 2024: 61 · 2023: 66 · 2022: 84 · 2021: 90 · 2020: 75 · 2019: 109 · 2018: 101 · 2017: 97 · 2016: 78
- FWCI
- 142.16
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by-nc-nd)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- eSpace (Curtin University) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Leicester Research Archive (University of Leicester) (submittedVersion, other-oa)
- Funders
- AstraZeneca
- Canadian Institutes of Health Research (IR2-91038))
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- rosuvastatin, statins, cholesterol lowering, intermediate cardiovascular risk, primary prevention, cardiovascular events, LDL cholesterol, ethnic diversity, C-reactive protein, cataract surgery, statin adverse effects, muscle symptoms, diabetes risk, cardiovascular mortality, myocardial infarction, stroke, heart failure, revascularization, cardiac arrest, cardiovascular risk stratification, lipid-lowering therapy
- MeSH terms
- Rosuvastatin Calcium, Aged, Cardiovascular Diseases, Double-Blind Method, Female, Humans, Hypercholesterolemia, Cholesterol, LDL, Male, Middle Aged, Risk Factors, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Medication Adherence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
